ClinicalTrials.gg
Sign In
Drug

SGN-LIV1A clinical trials

Also written SGN-LIV1A and ladiratuzumab vedotin.

studies test it
5
open now
2
in phase 3
0
first study started
2010

How each study uses SGN-LIV1A has had a first review. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the SGN-LIV1A studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

LV
2

Development codes

SGN-LIV1A
5

Other names

ladiratuzumab vedotin
3

Studies by the year they started

5 studies that test it; most in 2018 (2)

Studies that test SGN-LIV1A, by start year
YearStudies
20101
20131
20182
20191

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Triple Negative Breast Neoplasms
3
Breast Neoplasms
1
Small Cell Lung Carcinoma
1

Who runs them

Industry 4 · Other 1

Seagen Inc. (3) · Hoffmann-La Roche (1) · QuantumLeap Healthcare Collaborative (1)

Often tested with

Tested in the same studies.

Ipatasertib (1) · Bevacizumab (1) · Selicrelumab (1) · Tocilizumab (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Sacituzumab govitecan (1) · Inavolisib (1)

Studies

Open first, then newest update. How each study uses SGN-LIV1A has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 5

Tested with established drugs · 3 — they are given beside it
Tested in a combination · 2 — another drug in the study is under test too
Observed · 1 — patients on it are followed, or it is given outside a trial

Codes

What other systems call SGN-LIV1A · ClinicalTrials.gg INT000287

  • MeSH (NLM) C000600157SGN-LIV1AOne source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion